Progressive multifocal leukoencephalopathy risk stratification

A compelling need exists for a more reliable risk evaluation of natalizumab-associated progressive multifocal leukoencephalopathy (PML). A new report proposes a refined protocol that uses updated patient-based data and cumulative risk evaluation to provide an improved assessment of the annual risk of PML for patients positive for JC virus.